Clinical Trial Update: Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Lunacalcipol (CTA018) for chronic kidney disease stage 5 with secondary hyperparathyroidism has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease Stage
• Hyperparathyroidism

Drugs mentioned

• Lunacalcipol

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | Phase 2 | Status: WITHDRAWN